Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
AVAILABLE
NCT05028166
Individual Patient Compassionate Use of Mirdametinib
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
View on ClinicalTrials.gov
Summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-10-05
Healthy Volunteers
Not specified
Conditions
Interventions
DRUG
Mirdametinib (MEK Inhibitor)
Patients will receive oral mirdametinib.
Locations (2)
Please Contact U.S. Medical Information
Billerica, Massachusetts, United States
Please Contact the Communication Center
Darmstadt, Germany